Investors Sue Regencell Bioscience Following Federal Trading Investigation
New York, Monday, 27 April 2026.
Following a Department of Justice probe into alleged market manipulation that wiped out 18 percent of its stock value, Regencell Bioscience now faces mounting investor lawsuits.
Regulatory Scrutiny and Market Fallout
The catalyst for the current wave of litigation traces back to October 31, 2025, when Regencell Bioscience Holdings Limited (NASDAQ: RGC) disclosed a significant regulatory development in a filing with the U.S. Securities and Exchange Commission [2]. The biotechnology firm announced it had received correspondence and a subpoena from the U.S. Department of Justice (DOJ) [2]. The federal inquiry specifically targeted the trading activity of the company’s ordinary shares following a period of pronounced market volatility [2]. Corporate leadership acknowledged the severity of the probe, warning investors that the company expected to incur substantial legal expenses and could face fines, penalties, or damages that might exceed any existing insurance coverage [2].
Mounting Legal Action from Shareholders
In response to the steep decline in valuation, multiple prominent shareholder rights law firms have mobilized. On April 24, 2026, the San Diego-based firm Robbins LLP announced it had filed a class action lawsuit on behalf of affected investors [2][3]. Days later, on April 27, 2026, the New York-based law firm Gainey McKenna & Egleston announced the filing of a separate securities class action in the United States District Court for the District of Maryland [1]. Both legal actions aim to consolidate claims from individuals and entities who purchased or acquired Regencell securities during a specific timeframe, identified as the “Class Period,” which runs from October 28, 2024, to October 31, 2025, inclusive [1][2].
Next Steps for Affected Investors
As the litigation proceeds, shareholders who suffered financial losses during the Class Period are being urged to evaluate their legal options. Gainey McKenna & Egleston has established a June 23, 2026, deadline for investors to file a motion to serve as the lead plaintiff [1]. A lead plaintiff functions as a representative party, directing the course of the litigation on behalf of all absent class members [1][2]. Robbins LLP has noted that representation is being offered on a contingency fee basis, meaning participating shareholders are not required to pay upfront fees or expenses [2].